Formula I Compounds Inhibiting B-Raf Kinase to Treat Melanoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with abnormal B-Raf kinase activity, such as metastatic melanomas and solid tumors, are limited in effectiveness due to the challenges of inhibiting B-Raf kinase activity without affecting normal tissues and the emergence of resistance to selective Raf kinase inhibitors.
Innovation Solution
Development of novel compounds of Formula I, which inhibit B-Raf kinase activity by targeting specific kinase domains, including mutant forms like V600E, to treat diseases by administering a therapeutically effective amount of these compounds, either alone or in combination with MEK inhibitors, to selectively inhibit cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective Raf kinase inhibitors are used to treat B-Raf-associated diseases, then B-Raf kinase activity is inhibited, but resistance emerges and effectiveness is limited
Solution Approach 1:
The patent segments the treatment approach by combining two different mechanisms: B-Raf kinase inhibition and MEK inhibition. This dual-target strategy prevents resistance that develops against single-target inhibitors, as evidenced by the combination therapy maintaining effectiveness where monotherapy fails.
Solution Approach 2:
The patent creates a composite therapeutic approach by formulating compounds that can be used in combination with MEK inhibitors. This composite strategy addresses resistance by targeting multiple nodes in the signaling pathway simultaneously, ensuring sustained treatment effectiveness.
2Productivity
If B-Raf kinase activity is inhibited to treat cancer, then cancer cell proliferation is reduced, but toxicity to normal tissues occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (Formula I) that target B-Raf kinase selectively. The compounds exhibit preferential binding to mutant B-Raf (such as V600E) over wild-type B-Raf, achieving localized inhibition in cancer cells while sparing normal tissues.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the chemical structure of the compounds (Formula I) to achieve selective inhibition. By modifying molecular parameters such as substituent groups and stereochemistry, the compounds achieve enhanced selectivity for mutant B-Raf, reducing off-target effects on normal tissues.
Data Source
AI summary
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.